Download Document

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
BioSciencs Foro
Joaquin Guinea
Chairman of BIOMADRID
(www.biomadrid.org)
November 8th, New York
GLOBAL DATA ON THE REGION
OF MADRID R&D
•
288,800 people employed in the high technology sectors
(10.7% of the working population).
•
Investment in R&D: 2,400 million euros (1.76% of the GDP).
•
40,000 workers in R&D.
•
15 universities and more than 50 academic research centres.
•
230,000 university students and 2,000 doctorate students
every year.
•
27.3% of Spanish scientists are in Madrid and they produce
31% of the scientific publications in Spain.
•
More than 20 technology transfer centres.
•
Three fully operating scientific parks and another three under
construction.
MADRID BIOSCIENCE REGION IN
FIGURES
•
37 companies fully dedicated to biotechnology are located in
Madrid (32% of the total spanish companies). 83% of the
investment in R&D by biotechnology companies in Spain takes
place in Madrid.
•
400 biomedical companies (with around 25,000 workers) are
located in Madrid.
•
5,000 Life Sciences researchers work in academic centres in
Madrid.
•
31% of the Spanish biomedical scientific publications have its
origin in Madrid.
•
More than 300 new PhD graduates in Life Sciences every year.
•
More than 25,000 patients involved in more than 1,000 clinical
trials every year, in 75 hospital centres.
SOME EXAMPLES OF MADRID
BIOTECH COMPANIES
R&D PROJECTS
•
Cell Therapy based on the use of stem cells obtained from
adults.
•
Generation of new therapeutic molecules based on antibodies
for treatment of degenerative and inflammatory infectious
diseases.
•
Development of genetic engineering tools for medical diagnosis,
the agro-food industry and environmental control (clinical and
molecular diagnosis).
•
Development of precision analytical equipment by means of
biosensors (nanobiotechnology).
•
New systems to produce recombinant proteins in genetically
modified plants (with application in chemical&food industry) or
from insect larvae (with application in animal health).
•
Diagnosis and treatment of allergies by development of an
individualized molecular immunotherapy.
BIOTECH SECTOR SUPPORT
FROM PUBLIC SECTOR
• EUROPEAN COMMISION
• SPANISH GOVERNMENT
Ministery of Education
Ministery of Industry
• MADRID REGIONAL GOVERNMENT
Directorate General of Technological Innovation
Madrid Development Agency (IMADE)
PROMOMADRID
• MADRID CITY COUNCIL